InxMed

company

About

InxMed is a clinical-stage biotech company dedicated to developing innovative, individualized medicines with international impact.

  • Shanghai,Shanghai,China
  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$50M
Industries
Biotechnology,Life Science
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
InxMed (Shanghai) Co., Ltd.

InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equipped with global-level top-notch know-how and efficient execution capabilities.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$75M ¥130M
InxMed has raised a total of $75M ¥130M in funding over 2 rounds. Their latest funding was raised on Jul 21, 2022 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 21, 2022 Debt Financing $10M 1 SPD Silicon Valley Bank (SSVB) Detail
May 8, 2022 Series B $15M 1 Hyfinity Investments Detail
Mar 3, 2022 Series B $50M 4 CS Capital Detail
Sep 4, 2020 Series A ¥130M 4 Ennovation Ventures
China Growth Capital | CGC
Detail

Employee Profiles

Number of Employee Profiles
4
InxMed has 4 current employee profiles, including Board member Michael Keyoung
Board member
Executive
Executive
Executive